BRAINSTORM CELL THERAPEUTICS INC. Net Change in Cash
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported Net Change in Cash of $3.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-14
- BRAINSTORM CELL THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-06-30 was $3.00K.
- BRAINSTORM CELL THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$70.00K, a 104.81% decline year-over-year.
- BRAINSTORM CELL THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-09-30 was -$789.00K.
- BRAINSTORM CELL THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-06-30 was -$801.00K, a 129.81% decline year-over-year.
- BRAINSTORM CELL THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$95.00K.
- BRAINSTORM CELL THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$1.11M, a 256.24% decline from fiscal 2023.
- BRAINSTORM CELL THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $713.00K.
- BRAINSTORM CELL THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$18.08M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.00K 10-Q · filed 2026-08-14 | -$67.00K 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | -$70.00K 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | -$95.00K 10-K · filed 2026-03-31 | |||
| 2025-09-30 | -$789.00K 10-Q · filed 2025-11-14 | -$135.00K 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | -$801.00K 10-Q · filed 2026-08-14 | $654.00K 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | $1.46M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | -$1.11M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | -$3.30M 10-Q · filed 2025-11-14 | -$1.14M 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $2.69M 10-Q · filed 2025-08-14 | $2.16M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | -$524.00K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $713.00K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $676.00K 10-Q · filed 2024-11-14 | $450.00K 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | -$1.48M 10-Q · filed 2024-08-14 | -$226.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $1.25M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$18.08M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$4.86M 10-Q · filed 2023-11-14 | -$14.71M 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | -$6.15M 10-Q · filed 2023-08-14 | -$9.85M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$3.71M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$18.97M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | -$4.87M 10-Q · filed 2022-11-14 | -$12.13M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$5.37M 10-Q · filed 2022-08-15 | -$7.26M 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | -$1.90M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $37.29M 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $12.62M 10-Q · filed 2021-11-15 | $24.23M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$318.00K 10-Q · filed 2021-08-05 | $11.62M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $11.94M 10-Q · filed 2021-04-26 | |||
| 2019-12-31 | -$406.00K 10-K · filed 2021-02-04 | |||
| 2019-09-30 | $969.00K 10-Q · filed 2020-10-15 | $1.15M 10-Q · filed 2020-10-15 | ||
| 2019-06-30 | -$2.11M 10-Q · filed 2020-08-05 | $184.00K 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $2.30M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | -$1.54M 10-K · filed 2020-02-18 | |||
| 2018-09-30 | -$1.56M 10-Q · filed 2019-11-14 | -$1.79M 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |